Baricitinib
|
|
Baricitinib Eigenschaften
- Schmelzpunkt:
- 212-215°C
- Dichte
- 1.56
- storage temp.
- -20°C
- L?slichkeit
- Soluble in DMSO (up to 30 mg/ml) or in DMF (up to 50 mg/ml).
- pka
- 11.66±0.50(Predicted)
- Aggregatzustand
- solid
- Farbe
- White or off-white
- Stabilit?t:
- Stable for 2 years from date of purchase as supplied. Solutions in DMSO or DMF may be stored at -20°C for up to 3 months.
- InChI
- InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20)
- InChIKey
- XUZMWHLSFXCVMG-UHFFFAOYSA-N
- SMILES
- N1(S(CC)(=O)=O)CC(N2C=C(C3N=CN=C4NC=CC4=3)C=N2)(CC#N)C1
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
HS Code | 29350090 |
---|
Bildanzeige (GHS) |
![]() |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alarmwort | Warnung | ||||||||||||||
Gefahrenhinweise |
|
||||||||||||||
Sicherheit |
|
Baricitinib Chemische Eigenschaften,Einsatz,Produktion Methoden
Charakteristisch
Primary targets: JAK1/2Class: non-receptor tyrosine kinase
Treatment: rheumatoid arthritis
Oral bioavailability = 79%
Elimination half-life = 12.5 h
Protein binding = 50%
Verwenden
Baricitinib is a JAK1 and JAK2 inhibitor and have been used as a promising treatment for rheumatoid arthritis.Baricitinib Upstream-Materialien And Downstream Produkte
Upstream-Materialien
(4-(1-(3-(cyanomethyl)-1-(ethylsulfonyl)azetidin-3-yl)-1H-pyrazol-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl pivalate
Ethansulfonylchlorid
2-(1-(ethylsulfonyl)azetidin-3-ylidene)acetonitrile
2-(1-(ethylsulfonyl)-3-(4-(7-((2-(trimethylsilyl)ethoxy)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile
1-Boc-3-(cyanomethylene)azetidine
4-Chloro-7H-pyrrolo[2,3-d]pyrimidine
Downstream Produkte
Baricitinib Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 507)Lieferanten
Firmenname | Telefon | Land | Produktkatalog | Edge Rate | |
---|---|---|---|---|---|
TAIZHOU YUXIN BIOTECHNOLOGY CO,.LTD | +86-576-88902229;+86-0576-88902229 +8613968687450 |
yuxin@yuxchem.com | China | 167 | 58 |
AFINE CHEMICALS LIMITED | +86-0571-85134551 |
sales@afinechem.com | China | 15350 | 58 |
Changsha Junyu Chemexpress.co., Ltd | +86-13723890100 |
info@csjyyy.cn | China | 134 | 58 |
Jinan Million Pharmaceutical Co., Ltd | 0531-68659554 +8613031714605 |
info@millionpharm.com | China | 295 | 58 |
Beijing Hope Pharmaceutical Co., Ltd. | +86-010-67886402 +8613611125266 |
market@hopelife.cn | China | 72 | 58 |
Shandong Hanjiang Chemical Co., Ltd | +86-0533-2066820 +8618369939125 |
hanson@sdhanjiang.com | China | 1009 | 58 |
Guangzhou Tosun Pharmaceutical Ltd | +86-020-61855200-902 +8618124244216 |
info@upharm.cn | China | 897 | 58 |
Hebei Chuanghai Biotechnology Co., Ltd | +86-15531157085 +86-15531157085 |
abby@chuanghaibio.com | China | 8806 | 58 |
Hebei Mujin Biotechnology Co.,Ltd | +86 13288715578 +8613288715578 |
sales@hbmojin.com | China | 12820 | 58 |
shandong perfect biotechnology co.ltd | +86-53169958659 +86-13153181156 |
sales@sdperfect.com | China | 294 | 58 |
- 1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyriMidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile
- Baricitinib
- INCB 028050
- LY 3009104
- BARICITINIB;INCB28050;LY3009104
- Baricitinib (LY3009104)
- 2-(3-(4-(3H-Pyrrolo[2,3-d]pyriMidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile
- Baricitinib/INCB 028050/LY3009104
- 3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-
- 1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidineacetonitrile Baricitinib (LY3009104, INCB028050)
- 2-(3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile
- Baricitinib(INCB 028050
- Baricitinib, >=98%
- aricitinib (LY3009104, INCB028050)
- INCB028050; INCB-028050; INCB 028050; LY3009104; LY-3009104; LY 3009104; BARICITINIB; OLUMIANT
- Baricitinib Chemical Structure
- CS-574
- pharmaceutical grade and factory supply with Baricitinib CAS 1187594-09-7
- Baricitinib-API
- Barrettinib
- Baricitinib-007
- INCB028050 LY 3009104
- Baricitinib USP/EP/BP
- Baloxavir axetil
- 2-[1-(ethanesulfonyl)-3-(4-{7H-pyrrolo[2,3-d]pyrimi din-4-yl}-1H-pyrazol-1-yl)azetidin-3-yl]acetonitrile
- Baricitinib (LY3009104, INCB028050)
- Olumiant
- Barrickini
- Baracitinib
- 1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile
- Inhibitor,LY-3009104,JAK,Janus kinase,Baricitinib,INCB 028050,LY 3009104,INCB-028050,inhibit
- 2-1-Ethylsulfonyl-3-4-(7H-pyrrolo2,3-dpyrimidin-4-yl)-1H-pyrazol-1-ylazetidin-3-ylacetonitrile
- Baricinix
- Baritinib
- Baricitinib(For R & D only)
- Barectinib
- Baricitinib, 10 mM in DMSO
- 1187594-09-7
- 1187594-07-9
- JAK
- STAT
- API
- Inhibitors
- Inhibitor
- JAK/STAT
- 1187594-09-7
- 1